Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals has named Dr. Leonardo Viana Nicacio as chief medical officer. Nicacio brings more than 20 years of experience in the pharmaceutical industry, most recently as CMO at Protara Therapeutics and previously in senior clinical roles at Seagen. Corbus plans a regulatory Phase II study this summer for CRB-701 in oropharyngeal squamous cell carcinomas and expects results from the Phase 1b CANYON-1 study for CRB-913 against obesity by late summer 2026. According to an analysis, the company has more cash than debt but is burning capital and is not expected to be profitable in 2026. » More on de.investing.com

Corbus Pharmaceuticals shares fell about 9.6% pre-market after the release of updated phase‑1/2 data on CRB‑701. In squamous cell carcinomas of the oropharynx, CRB‑701 (3.6 mg/kg) showed a confirmed ORR of 42.9%, median duration of response 6.3 months and median PFS of 5.6 months; in cervical cancer the ORR was 34.4%, duration of response 8.0 months and PFS 4.3 months. The analysis (safety population n=317) showed an acceptable safety profile with 2.8% treatment‑related discontinuations and a planned start of a registration‑enabling randomized phase study (250 patients) in summer 2026 after broad alignment with the FDA. » More on de.investing.com

Corbus Pharmaceuticals has appointed Brent Pfeiffenberger to its board of directors. Pfeiffenberger is CEO of Century Therapeutics and brings experience from leadership roles at Neogene Therapeutics and Bristol Myers Squibb. The appointment comes ahead of the presentation of updated phase‑1/2 data for CRB‑701 at ASCO and the planned start of a registration‑enabling second‑line trial for CRB‑701 in the summer. In addition, the phase‑1b CANYON‑1 study of CRB‑913 with 240 participants is expected to be completed on schedule in summer 2026. » More on de.investing.com